Home Featured

Featured

Random

Psychedelica Europa: A Deep Dive Into the Latest Psychedelic Research, Regulations and Policy

AP News – Psychedelics Today Launches “Psychedelics Tonight”

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

PT330 – Dick Simon – Researching Ethnobotanical Efficacy and the Search For New Therapeutic Molecules

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

Psychedelics Weekly – Psilocybin and Stress Response, the Minnesota Medical Association...

Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Q3’25 Survey: What are Psychedelics Investors Excited About?

Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and...

Psyence Awarded ISO Certification through the British Standards Institute for its...

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals...

PT482 – Behind the Scenes: A Conversation on Psychedelic Business, Media,...

COMPASS Pathways to participate in upcoming September investor conferences

Red Light Holland to Partner with Leading Fresh and Dried Mushroom...

Delix Therapeutics Expands Executive Leadership Team

12 3...327 Page 1 of 327

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.